Welcome to our dedicated page for Kewaunee Scienti SEC filings (Ticker: KEQU), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to Kewaunee Scientific Corporation’s (NASDAQ: KEQU) SEC filings, allowing investors and researchers to review the company’s official regulatory disclosures. Kewaunee files reports and current event disclosures with the U.S. Securities and Exchange Commission as a public company listed on The Nasdaq Global Market.
In these filings, users can find quarterly and annual financial information, including discussions of segment performance for the domestic, international, and corporate segments. The company also explains its use of non-GAAP measures such as EBITDA, Segment EBITDA, Adjusted EBITDA, adjusted net earnings, and adjusted net earnings per share, and provides reconciliations to the most comparable GAAP measures.
Kewaunee’s Form 8-K current reports cover topics such as quarterly and annual results, amendments to bylaws, board appointments, annual meeting outcomes, and the timing of earnings releases. Proxy materials, such as the company’s definitive proxy statement, describe matters submitted to shareholders, including director elections, auditor ratification, advisory votes on executive compensation, and the frequency of such advisory votes.
Filings also document capital markets and governance actions, including details of share repurchase program approvals or amendments, loan agreements and related disclosures, and information about non-employee director compensation and committee assignments. Together, these documents provide a structured view of Kewaunee’s financial condition, governance framework, and significant corporate events.
On Stock Titan, KEQU filings are updated in step with new submissions to the SEC’s EDGAR system. AI-powered summaries highlight key points from long-form documents, helping users quickly understand the main changes, financial metrics, and governance decisions without reading every page of each filing.
Form 144 notice by an insider of Kewaunee Scientific Corp (KEQU) discloses a proposed sale of 1,000 common shares through Fidelity Brokerage Services (Boston) with an aggregate market value of $42,720, and lists prior open-market sales by the same person totaling 5,000 shares across five transactions between September 18–29, 2025, generating gross proceeds shown for each trade. The 1,000 shares were acquired as a stock award on June 30, 2024 and were issued as compensation. The filer certifies they are not aware of undisclosed material adverse information about the issuer.
Thomas David Hull III, President, CEO and director of Kewaunee Scientific Corp (KEQU), reported two open-market sales of common stock on September 23-24, 2025. He sold 721 shares on 09/23/2025 at a weighted-average price shown as $44 and an additional 1,000 shares on 09/24/2025 at a weighted-average price shown as $43.62. After the September 23 trade his beneficial ownership was 42,573 shares and after the September 24 trade it was 41,573 shares. The form was signed by an attorney-in-fact on 09/24/2025. The filing includes a note that reported prices are weighted averages and that the filer will provide breakdowns on request.
Thomas David Hull III, who serves as President, CEO and a director of Kewaunee Scientific Corp (KEQU), reported two insider sales of common stock on September 18 and 19, 2025. On 09/18/2025 he sold 652 shares at a weighted average price of $46 (price range $46.00–$46.03), leaving him with 44,067 shares beneficially owned after that transaction. On 09/19/2025 he sold 773 shares at a weighted average price of $45.34 (price range $45.21–$45.71), with 43,294 shares reported beneficially owned following that sale. The Form 4 was executed by an attorney-in-fact and includes standard explanatory remarks about weighted average pricing.
Campbell John Jette, identified as a director of Kewaunee Scientific Corp (KEQU), filed an initial Section 16 Form 3 reporting the transaction date 09/10/2025. The filing states no securities are beneficially owned by the reporting person and includes a power of attorney (Exhibit 24) with the form signed by an attorney-in-fact on 09/11/2025. This is an initial ownership disclosure showing the director currently holds no reportable equity.
Kewaunee Scientific announced the appointment of Mr. Campbell to its Board and approved amended bylaws. Mr. Campbell brings extensive finance and restructuring experience from roles at Carl Marks Advisors and prior executive positions at Griffin LLC, PepsiCo and Frito-Lay, and is a certified public accountant with decades in public accounting and corporate finance. The Board determined he meets Nasdaq and SEC independence and financial literacy requirements and has named him to the Audit Committee.
The company said Mr. Campbell will be paid under the standard non-employee director program and will receive a pro-rated equity grant for fiscal 2026. The Board also amended Section 5.02 of the Bylaws to set the Board size at a minimum of five and maximum of nine directors, with the exact number fixed by Board resolution.
FAQ
What is the current stock price of Kewaunee Scienti (KEQU)?
What is the market cap of Kewaunee Scienti (KEQU)?
